
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
A new study finds that Retail clinic's revenues could reach nearly $4.5 billion by 2011.
By 2011,
To see more Daily News articles,
To go to the Drug Topics homepage,





